Loading...
01/10 16:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals: strong revenue growth and gross margins, yet a significant cash burn and lack of 2025 guidance. The acquisition of NeuroMetrix adds complexity, while market access risks and operational challenges persist. The Q&A session highlighted management's lack of clarity on margin estimates and revenue growth projections, which could concern investors. Despite positive developments like the Truvaga expansion and distribution agreement, the absence of a shareholder return plan and cash flow risks temper optimism, leading to a neutral stock price prediction.
Revenue $6.7 million, a 23% increase from $5.4 million in Q1 2024, driven by increased sales of prescription gammaCore devices and non-prescription Truvaga products.
Gross Profit $5.7 million, up from $4.6 million in Q1 2024, primarily due to the increase in net sales.
Gross Margin 85%, compared to 84% in Q1 2024, reflecting improved sales performance.
Prescription gammaCore VA Revenue $4.7 million, a 22% increase from $3.9 million in Q1 2024, attributed to increased purchases by VA facilities.
Truvaga Net Sales $1.1 million, a 187% increase from Q1 2024, driven by effective advertising and increased consumer awareness.
U.S. Prescription Channel Revenue $289,000, down 33% from Q1 2024, as cash pay customers migrated to the Truvaga brand.
Revenue from Outside the U.S. (OUS) $513,000, up from $449,000 in Q1 2024, primarily from prescription gammaCore sales in the UK.
Total Operating Expenses $9.5 million, compared to $8.4 million in Q1 2024, due to increased investment in sales and marketing and year-end reporting expenses.
GAAP Net Loss $3.9 million, compared to $3.5 million in Q1 2024, attributed to changes in below-the-line items and increased transaction fees.
Net Loss per Share $0.47, compared to $0.53 in Q1 2024, indicating a slight improvement in loss per share.
Adjusted EBITDA Net Loss $3.1 million, flat compared to $3.2 million in Q1 2024, showing stability in operational performance.
Cash and Cash Equivalents Approximately $8 million as of March 31, 2025, down from $12.2 million as of December 31, 2024, due to higher cash disbursements.
Net Cash Used in Operating Activities $4.4 million, compared to $1.3 million in Q4 2024, due to seasonal expenses and changes in working capital.
Truvaga: In Q1 2025, Truvaga net sales were approximately $1.1 million, a 187% increase from Q1 2024. The brand is expanding with new product offerings and channels, including a successful launch on Amazon.
Quell: The acquisition of the Quell product line from NeuroMetrix is a key strategic move, expected to enhance revenue from fibromyalgia treatments. Quell revenue was $170,000 in Q1 2025, with plans to increase production.
Sparrow Ascent: A distribution agreement with Spark Biomedical was announced for the Sparrow Ascent product line, targeting opioid withdrawal treatment, with plans to launch in VA hospitals in Q2 2025.
VA Hospital System: Revenue from the VA channel grew, with prescription gammaCore revenue increasing 22% to $4.7 million in Q1 2025. The company is regaining momentum after a slowdown.
International Expansion: Revenue from outside the U.S. increased to $513,000 in Q1 2025, with plans to launch Truvaga in the U.K. and Canada later this year.
Sales Growth: Total revenue for Q1 2025 was $6.7 million, a 23% increase year-over-year, with gross margins at 85%.
Field Sales Expansion: The company is increasing field sales headcount to drive growth, with 49 active sales agents as of May 2025.
Acquisition of NeuroMetrix: The acquisition is aimed at becoming a leader in bioelectronic health and wellness, enhancing product offerings and market reach.
New FSS Contract: A new Federal Supply Schedule contract effective June 15, 2025, will support the distribution of Quell and Sparrow products.
Competitive Pressures: The company faces competitive pressures in the bioelectronic health and wellness sector, particularly as it expands its product offerings and distribution channels.
Regulatory Issues: The company must navigate regulatory requirements associated with the FDA authorization of its products, including the Quell fibromyalgia device.
Supply Chain Challenges: There are supply limitations due to the need to restart production at the Rockaway facility, which may affect revenue from the Quell product line in the short term.
Economic Factors: The company is impacted by macroeconomic forces that previously slowed growth in the VA hospital system, although these headwinds are reportedly abating.
Cash Flow Risks: The company used approximately $4.2 million in cash during Q1 2025 and anticipates needing an additional $4 million in net cash for the remainder of the year, indicating potential cash flow risks.
Market Access Risks: The company is evaluating market access through third-party payer systems and hospital networks, which may present challenges in expanding its prescription product suite.
Operational Complexity: The acquisition of NeuroMetrix adds complexity to the business operations, requiring adjustments in reporting revenue by channel and product category.
Acquisition of Quell Product Line: The acquisition of the Quell product line from NeuroMetrix, Inc. is a key strategic initiative aimed at broadening electroCore's addressable market and diversifying revenue.
Expansion of Truvaga Brand: The Truvaga brand is being expanded through new product offerings and channels, including a recent launch on Amazon and integration with the Apple Health app.
Sales Growth in VA Channel: The company is regaining momentum in the VA hospital system, with a return to sequential growth after a slowdown, and plans to increase field sales headcount.
New Distribution Agreement: A distribution agreement with Spark Biomedical for the Sparrow Ascent product line aims to address opioid withdrawal symptoms, with plans to expand distribution in the VA hospital system.
Revenue Expectations for 2025: Total revenue for 2025 is expected to be approximately $30 million.
Cash Usage Projections: Net cash used for operations is projected to be between $3.8 million and $4.3 million for the full year of 2025.
Path to Profitability: The business could be cash neutral with quarterly revenue of about $9 million, expected towards the end of 2025 or early 2026.
Gross Margin Outlook: Gross margins are expected to remain in the mid-80s for the foreseeable future.
Shareholder Return Plan: None
The earnings call reflects mixed signals. Basic financial performance shows slight improvement in adjusted EBITDA net loss, but there's a delay in profitability. Product development is active, but with uncertainties in TAC-STIM and international revenue. Market strategy is cautious, with some success in VA channels. Expenses are increasing, impacting financial health. Shareholder returns are not addressed. Q&A reveals cautious expansion and litigation issues. Overall, the stock price reaction is likely neutral due to balanced positive and negative elements.
The earnings call presents mixed signals. The VA revenue growth and Truvaga's year-over-year sales increase are positives. However, the sequential decline in Truvaga sales, increased operating expenses, and net loss raise concerns. The Q&A highlights uncertainties around patent litigation and unclear marketing spend impacts. While new product lines and integrations offer potential, the lack of specific guidance and profitability delays temper optimism. Given these factors, the stock price reaction is likely to remain neutral.
The earnings call reveals mixed signals: strong revenue growth and gross margins, yet a significant cash burn and lack of 2025 guidance. The acquisition of NeuroMetrix adds complexity, while market access risks and operational challenges persist. The Q&A session highlighted management's lack of clarity on margin estimates and revenue growth projections, which could concern investors. Despite positive developments like the Truvaga expansion and distribution agreement, the absence of a shareholder return plan and cash flow risks temper optimism, leading to a neutral stock price prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
